Ann Surg 2020 Dec 22. Epub 2020 Dec 22.
*Thomas Jefferson University Hospital and The Jefferson Pancreas, Biliary and Related Cancer Center, Philadelphia, PA †Cedars Sinai Medical Center, Los Angeles, CA ‡University of Oklahoma, Oklahoma City, OK §Baylor College of Medicine, Houston, TX ¶Virginia Piper Cancer Institute, Minneapolis, MN ||University of Washington-Seattle Cancer Care, Seattle, WA **University of Kansas Cancer Center, Westwood, KS ††H. Lee Moffitt Cancer Center, Tampa, FL ‡‡Oregon Health and Science University, Portland, OR §§University of Wisconsin, Madison, WI ¶¶University of Florida, Gainesville, FL ||||Boca Raton Hospital, Boca Raton, FL ***University of California at Irvine, Irvine, CA †††NewLink Genetics Corporation, Ames, IA ‡‡‡Lumos Pharma Inc, Ames, IA.
Objectives: To compare the efficacy and safety of algenpantucel-L (HAPa; IND# 12311) immunotherapy combined with standard of care (SOC) chemotherapy and chemoradiation to SOC chemotherapy and chemoradiation therapy alone in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (PDAC).
Summary Background Data: To date, immunotherapy has not been shown to benefit patients with borderline resectable or locally advanced unresectable PDAC. HAPa is a cancer vaccine consisting of allogeneic pancreatic cancer cells engineered to express the murine α(1,3)GT gene. Read More